Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT

Descriptive Study Comparing Regadenoson Versus Dipyridamole in Use as Pharmacological Stress Agent Before a Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (SPECT)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03084562

Acronym

REDUCE

Enrollment

300

Registered

2017-03-21

Start date

2017-05-03

Completion date

2017-10-09

Last updated

2018-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Perfusion Imaging

Brief summary

Myocardial perfusion scintigraphy is to evaluate coronary perfusion as well as heart muscle function. This examination takes place in two stages, one imaging at rest and one after a cardiac stress caused. This stress can be triggered as a first-line stress test. A pharmacological stress is proposed when stress test is not possible or contraindicated, Several drugs have a marketing authorization in this indication (adenosine, dipyridamole, regadenoson, dobutamine). Among them, the regadenoson is the most recent molecule. Marketed in France since 2013, it would allow a reduction of undesirable effects compared to other agents, especially adenosine. It is simple and quick to use thanks to a single dose administration. However, its cost is nearly 30 times higher than dipyridamole. In the investigational center, dipyridamole is currently the first-line pharmacological stress agent, whereas regadenoson is reserved for a limited number of doses, the indication of which must be justified (asthmatic patient or with severe COPD). Few studies in the literature specifically compare these two pharmacological agents (examination time, cost, tolerance) and the opinion on the use of regadenoson in the service is limited.

Interventions

OTHERcollect examination time, functional and clinical tolerability

Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult ≥ 18 years * Myocardial scintigraphy by pharmacological stress agent * Used molecules = Dipyridamole or Regadenoson

Exclusion criteria

* Physical stress test by single or mixed effort (associating pharmacological stress) * Pharmacological agent used = Adenosine * Inclusion in the ERCAD protocol * Double isotope protocol * Patient refusal due to study information

Design outcomes

Primary

Measure	Time frame	Description
Duration of the test	24 hours (Visit 1: During the examen)	Evaluate the time savings from the use of regadenoson versus dipyridamole by comparing the duration of the test.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026